Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus

Rheumatology (Oxford). 2022 Aug 3;61(8):3317-3328. doi: 10.1093/rheumatology/keab877.

Abstract

Objective: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving a lymphodepleting, reduced intensity regimen for AHSCT in SLE.

Methods: Eight patients with SLE refractory to treatment, including i.v. cyclophosphamide (CYC), were enrolled. Five had LN and three CNS involvement as primary indications for transplant. Haematopoietic cell mobilization with CYC, G-CSF and rituximab was followed by collection of CD34+ positively selected cells. The conditioning regimen consisted of concurrent administration of CYC, fludarabine and rituximab. All immunosuppressive medications were discontinued at the start of mobilization and CS were rapidly tapered after the transplant.

Results: Five of eight patients achieved a complete response, including a decline in the SLEDAI to zero, which was sustained in four patients for a median of 165 months (range 138-191). One patient achieved a partial response, which was followed by relapse at month 18. Two patients with nephritis and underlying comorbidities in most organs had early deaths from infection and multiorgan failure. AHSCT resulted in profound lymphodepletion, followed by expansion of Treg cells and repopulation of naive T and B cells. Patients with a complete response showed a sustained suppression of the SLE-associated IFN-induced gene signature, marked depletion of memory and plasmablast B cells and resultant sustained elimination of anti-dsDNA antibody.

Conclusion: Durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory SLE following lymphodepleting AHSCT.

Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00076752.

Keywords: SLE; cytokine; interferon; lymphodepletion; stem cell transplantation.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Antibodies, Antinuclear
  • Cyclophosphamide / therapeutic use
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Lupus Erythematosus, Systemic*
  • Rituximab / therapeutic use
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Antibodies, Antinuclear
  • anti-dsDNA autoantibody
  • Rituximab
  • Cyclophosphamide

Associated data

  • ClinicalTrials.gov/NCT00076752